StockData
Arvinas, Inc. logo

Arvinas, Inc. (ARVN) stock

ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$6.76−0.06 (-0.81%)

Close on Nov 18, 2026Market cap $442.34MP/E 42.3Yield –

Arvinas operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Arvinas's operating income for the twelve months ending Jun 30, 2026 was -$18.10M. For fiscal 2025 it was -$118.50M. The highest annual figure on record is -$24.76M in fiscal 2017.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$118.50M–
FY2024Dec 31, 2024-$250.20M–
FY2023Dec 31, 2023-$401.50M–
FY2022Dec 31, 2022-$263.20M–
FY2021Dec 31, 2021-$188.40M–
FY2020Dec 31, 2020-$120.80M–
FY2019Dec 31, 2019-$51.50M–
FY2018Dec 31, 2018-$43.80M–
FY2017Dec 31, 2017-$24.76M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$164.10M–
Q1 FY2026Mar 31, 2026-$63.80M-189.4%
Q4 FY2025Dec 31, 2025-$74.60M–
Q3 FY2025Sep 30, 2025-$43.80M–
Q2 FY2025Jun 30, 2025-$71.50M–
Q1 FY2025Mar 31, 2025$71.40M–
Q4 FY2024Dec 31, 2024-$58.20M–
Q3 FY2024Sep 30, 2024-$60.30M–
Q2 FY2024Jun 30, 2024-$48.50M–
Q1 FY2024Mar 31, 2024-$83.30M–
Q4 FY2023Dec 31, 2023-$165.30M–
Q3 FY2023Sep 30, 2023-$73.90M–
Q2 FY2023Jun 30, 2023-$74.60M–
Q1 FY2023Mar 31, 2023-$87.70M–
Q4 FY2022Dec 31, 2022-$75.60M–
Q3 FY2022Sep 30, 2022-$64.30M–
Q2 FY2022Jun 30, 2022-$65.80M–
Q1 FY2022Mar 31, 2022-$57.70M–
Q4 FY2021Dec 31, 2021-$47.50M–
Q3 FY2021Sep 30, 2021-$47.30M–
Q2 FY2021Jun 30, 2021-$51.90M–
Q1 FY2021Mar 31, 2021-$41.70M–
Q4 FY2020Dec 31, 2020-$39.16M–
Q3 FY2020Sep 30, 2020-$31.75M-676.7%
Q2 FY2020Jun 30, 2020-$26.48M–
Q1 FY2020Mar 31, 2020-$23.41M–
Q4 FY2019Dec 31, 2019-$22.79M–
Q3 FY2019Sep 30, 2019$5.50M–
Q2 FY2019Jun 30, 2019-$18.42M–
Q1 FY2019Mar 31, 2019-$15.81M–
Q4 FY2018Dec 31, 2018-$16.94M–
Q3 FY2018Sep 30, 2018-$14.06M–
Q2 FY2018Jun 30, 2018-$8.52M–
Q1 FY2018Mar 31, 2018-$4.28M–
Q4 FY2017Dec 31, 2017-$5.31M–
Q3 FY2017Sep 30, 2017-$6.41M–
Q2 FY2017Jun 30, 2017-$6.72M–
Q1 FY2017Mar 31, 2017-$6.32M–

More Arvinas figures

See a number that looks wrong?